Tectonic Therapeutic (TECX) Income from Non-Controlling Interests (2023 - 2026)
Tectonic Therapeutic (TECX) posted quarterly Income from Non-Controlling Interests of $25.2 million for Q1 2026, up 58.39% year-over-year from $15.9 million in Q1 2025, and up 30.95% quarter-over-quarter from $19.2 million in Q4 2025.
Analysis
Tectonic Therapeutic (TECX) Income from Non-Controlling Interests (2023 - 2026) Analysis & Trends
Tectonic Therapeutic (TECX) has reported Income from Non-Controlling Interests for 4 consecutive years, with $25.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Income from Non-Controlling Interests rose 58.39% year-over-year to $25.2 million; the TTM figure through Mar 2026 stood at $83.5 million (up 42.52% YoY), while the FY2025 annual figure was $74.3 million, up 28.09% from the prior year.
- Income from Non-Controlling Interests rose to $25.2 million in Q1 2026 per TECX's latest filing, from $19.2 million in the prior quarter.
- Across five years, Income from Non-Controlling Interests topped out at $25.2 million in Q1 2026 and bottomed at $7.9 million in Q4 2023.
- Historically, Income from Non-Controlling Interests has averaged $15.5 million across 4 years, with a median of $15.6 million in 2024.
- Annual changes were most pronounced in 2024 — Income from Non-Controlling Interests soared 76.38% — and 2025, when it advanced 4.2%.
- Tectonic Therapeutic's Income from Non-Controlling Interests stood at $7.9 million in 2023, then soared by 56.07% to $12.3 million in 2024, then jumped by 56.51% to $19.2 million in 2025, then surged by 30.95% to $25.2 million in 2026.
- Business Quant data shows TECX's Income from Non-Controlling Interests at $25.2 million in Q1 2026, $19.2 million in Q4 2025, and $19.1 million in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.62 Bn | 131.77 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.73 Bn | 77.73 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.53 Bn | 58.35 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.23 Bn | 53.09 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | - |
| 6 | BeOne Medicines | 40.03 Bn | 34.93 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.50 Bn | 32.19 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.52 Bn | 27.68 Bn | - | 63.60 Mn |
| 9 | Insmed | 27.46 Bn | 26.30 Bn | 358.27 Mn | - |
| 10 | Tectonic Therapeutic | 569.49 Mn | 569.49 Mn | - | 22.29 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 22.29 Mn |
| Mar 31, 2026 | 25.20 Mn |
| Dec 31, 2025 | 19.25 Mn |
| Sep 30, 2025 | 19.06 Mn |
| Jun 30, 2025 | 20.04 Mn |
| Mar 31, 2025 | 15.91 Mn |
| Dec 31, 2024 | 12.30 Mn |
| Sep 30, 2024 | 17.73 Mn |
| Jun 30, 2024 | 12.68 Mn |
| Mar 31, 2024 | 15.27 Mn |
| Dec 31, 2023 | 7.88 Mn |
| Sep 30, 2023 | 10.05 Mn |
| Jun 30, 2023 | 10.46 Mn |